Apollomics Inc. Warrant
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, … Read more
Apollomics Inc. Warrant (APLMW) - Total Assets
Latest total assets as of June 2024: $34.57 Million USD
Based on the latest financial reports, Apollomics Inc. Warrant (APLMW) holds total assets worth $34.57 Million USD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Apollomics Inc. Warrant - Total Assets Trend (2020–2023)
This chart illustrates how Apollomics Inc. Warrant’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Apollomics Inc. Warrant - Asset Composition Analysis
Current Asset Composition (December 2023)
Apollomics Inc. Warrant's total assets of $34.57 Million consist of 72.1% current assets and 27.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 57.9% |
| Accounts Receivable | $466.00K | 0.8% |
| Inventory | $-466.00K | -0.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $14.76 Million | 26.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2023)
This chart illustrates how Apollomics Inc. Warrant's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Apollomics Inc. Warrant's current assets represent 72.1% of total assets in 2023, a decrease from 92.8% in 2020.
- Cash Position: Cash and equivalents constituted 57.9% of total assets in 2023, down from 76.9% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, an increase from 6.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 26.6% of total assets.
Apollomics Inc. Warrant Competitors by Total Assets
Key competitors of Apollomics Inc. Warrant based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Apollomics Inc. Warrant - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Apollomics Inc. Warrant generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Apollomics Inc. Warrant is currently not profitable relative to its asset base.
Apollomics Inc. Warrant - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.25 | 3.92 | 5.88 |
| Quick Ratio | 2.25 | 3.92 | 5.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $15.76 Million | $ 41.24 Million | $ 62.47 Million |
Apollomics Inc. Warrant - Advanced Valuation Insights
This section examines the relationship between Apollomics Inc. Warrant's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -27.6% |
| Total Assets | $55.39 Million |
| Market Capitalization | $132.88 USD |
Valuation Analysis
Below Book Valuation: The market values Apollomics Inc. Warrant's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Apollomics Inc. Warrant's assets decreased by 27.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Apollomics Inc. Warrant (2020–2023)
The table below shows the annual total assets of Apollomics Inc. Warrant from 2020 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $55.39 Million | -27.58% |
| 2022-12-31 | $76.47 Million | -38.05% |
| 2021-12-31 | $123.44 Million | -27.36% |
| 2020-12-31 | $169.94 Million | -- |